|
1
|
Cohen SB, Graham ME, Lovrecz GO, Bache N,
Robinson PJ and Reddel RR: Protein composition of catalytically
active human telomerase from immortal cells. Science.
315:1850–1853. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Campisi J, Kim SH, Lim CS and Rubio M:
Cellular senescence, cancer and aging: the telomere connection. Exp
Gerontol. 36:1619–1637. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zvereva MI, Shcherbakova DM and Dontsova
OA: Telomerase: structure, functions, and activity regulation.
Biochemistry. 75:1563–1583. 2010.PubMed/NCBI
|
|
4
|
Raptis S and Bapat B: Genetic instability
in human tumors. EXS. 303–320. 2006.
|
|
5
|
Lü MH, Deng JQ, Cao YL, Fang DC, Zhang Y
and Yang SM: Prognostic role of telomerase activity in gastric
adenocarcinoma: a meta-analysis. Exp Ther Med. 3:728–734.
2012.PubMed/NCBI
|
|
6
|
Harley CB: Telomerase and cancer
therapeutics. Nat Rev Cancer. 8:167–179. 2008. View Article : Google Scholar
|
|
7
|
Onoda N, Ogisawa K, Ishikawa T, Takenaka
C, Tahara H, Inaba M, Takashima T and Hirakawa K: Telomerase
activation and expression of its catalytic subunits in benign and
malignant tumors of the parathyroid. Surg Today. 34:389–393. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sorbe B, Bohr L, Karlsson L and Bermark B:
Combined external and intracavitary irradiation in treatment of
advanced cervical carcinomas: predictive factors for local tumor
control and early recurrences. Int J Oncol. 36:371–378. 2010.
|
|
9
|
Shay JW and Wright WE: Implications of
mapping the human telomerase gene (hTERT) as the most distal gene
on chromosome 5p. Neoplasia. 2:195–196. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu ST, Chen L, Wang HJ, Tang XD, Fang DC
and Yang SM: hTERT promotes the invasion of telomerase-negative
tumor cells in vitro. Int J Oncol. 35:329–336.
2009.PubMed/NCBI
|
|
11
|
Park JI, Venteicher AS, Hong JY, Choi J,
Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, et al:
Telomerase modulates Wnt signalling by association with target gene
chromatin. Nature. 460:66–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanzawa T, Komata T, Kyo S, Germano IM,
Kondo Y and Kondo S: Down-regulation of telomerase activity in
malignant glioma cells by p27KIP1. Int J Oncol.
23:1703–1708. 2003.PubMed/NCBI
|
|
13
|
Papanikolaou V, Iliopoulos D, Dimou I,
Dubos S, Tsougos I, Theodorou K, Kitsiou-Tzeli S and Tsezou A: The
involvement of HER2 and p53 status in the regulation of telomerase
in irradiated breast cancer cells. Int J Oncol. 35:1141–1149.
2009.PubMed/NCBI
|
|
14
|
Meeran SM, Patel SN, Chan TH and
Tollefsbol TO: A novel prodrug of epigallocatechin-3-gallate:
differential epigenetic hTERT repression in human breast cancer
cells. Cancer Prev Res. 4:1243–1254. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang YF, Tang XD, Gao JH, Fang DC and
Yang SM: Heparanase: a universal immunotherapeutic target in human
cancers. Drug Discov Today. 16:412–417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amarnath SM, Dyer CE, Ramesh A, Iwuagwu O,
Drew PJ and Greenman J: In vitro quantification of the
cytotoxic T lymphocyte response against human telomerase reverse
transcriptase in breast cancer. Int J Oncol. 25:211–217. 2004.
|
|
17
|
Titu LV, Loveday RL, Madden LA, Cawkwell
L, Monson JR and Greenman J: Cytotoxic T-cell immunity against
telomerase reverse transcriptase in colorectal cancer patients.
Oncol Rep. 12:871–876. 2004.PubMed/NCBI
|
|
18
|
Naito K, Ueda Y, Itoh T, Fuji N, Shimizu
K, Yano Y, Yamamoto Y, Imura K, Kohara J, Iwamoto A, et al: Mature
dendritic cells generated from patient-derived peripheral blood
monocytes in one-step culture using streptococcal preparation
OK-432 exert an enhanced antigen-presenting capacity. Int J Oncol.
28:1481–1489. 2006.
|
|
19
|
Chen L, Liang GP, Tang XD, Chen T, Cai YG,
Fang DC, Yu ST, Luo YH and Yang SM: In vitro anti-tumor immune
response induced by dendritic cells transfected with hTERT
recombinant adenovirus. Biochem Biophys Res Commun. 351:927–934.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey
D, Turaga V, Higgins J, Boczkowski D, Gilboa E and Dannull J:
Enhanced induction of telomerase-specific CD4(+) T cells using
dendritic cells transfected with RNA encoding a chimeric gene
product. Cancer Res. 62:5041–5048. 2002.PubMed/NCBI
|
|
21
|
Chen M, Chen G, Deng S, Liu X, Hutton GJ
and Hong J: IFN-beta induces the proliferation of
CD4+CD25+Foxp3+ regulatory T cells
through upregulation of GITRL on dendritic cells in the treatment
of multiple sclerosis. J Neuroimmunol. 242:39–46. 2012.
|
|
22
|
Liu JP, Chen W, Schwarer AP and Li H:
Telomerase in cancer immunotherapy. Biochim Biophys Acta.
1805:35–42. 2010.PubMed/NCBI
|
|
23
|
Minev B, Hipp J, Firat H, Schmidt JD,
Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against
telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA.
97:4796–4801. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hernandez J, Garcia-Pons F, Lone YC, Firat
H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Identification of
a human telomerase reverse transcriptase peptide of low affinity
for HLA A2.1 that induces cytotoxic T lymphocytes and mediates
lysis of tumor cells. Proc Natl Acad Sci USA. 99:12275–12280. 2002.
View Article : Google Scholar
|
|
25
|
Scardino A, Gross DA, Alves P, Schultze
JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM,
Lemonnier FA, et al: HER-2/neu and hTERT cryptic epitopes as novel
targets for broad spectrum tumor immunotherapy. J Immunol.
168:5900–5906. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thorn M, Wang M, Kloverpris H, Schmidt EG,
Fomsgaard A, Wenandy L, Berntsen A, Brunak S, Buus S and Claesson
MH: Identification of a new hTERT-derived HLA-A*0201
restricted, naturally processed CTL epitope. Cancer Immunol
Immunother. 56:1755–1763. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schreurs MW, Hermsen MA, Geltink RI,
Scholten KB, Brink AA, Kueter EW, Tijssen M, Meijer CJ, Ylstra B,
Meijer GA and Hooijberg E: Genomic stability and functional
activity may be lost in telomerase-transduced human CD8+
T lymphocytes. Blood. 106:2663–2670. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mizukoshi E, Nakamoto Y, Marukawa Y, Arai
K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M and Kaneko S:
Cytotoxic T cell responses to human telomerase reverse
transcriptase in patients with hepatocellular carcinoma.
Hepatology. 43:1284–1294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Adotevi O, Mollier K, Neuveut C, Cardinaud
S, Boulanger E, Mignen B, Fridman WH, Zanetti M, Charneau P,
Tartour E, et al: Immunogenic HLA-B*0702-restricted
epitopes derived from human telomerase reverse transcriptase that
elicit antitumor cytotoxic T-cell responses. Clin Cancer Res.
12:3158–3167. 2006.PubMed/NCBI
|
|
30
|
Cortez-Gonzalez X, Sidney J, Adotevi O,
Sette A, Millard F, Lemonnier F, Langlade-Demoyen P and Zanetti M:
Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol.
18:1707–1718. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bernardeau K, Kerzhero J, Fortun A,
Moreau-Aubry A, Favry E, Echasserieau K, Tartour E, Maillere B and
Lang F: A simple competitive assay to determine peptide affinity
for HLA class II molecules: a useful tool for epitope prediction. J
Immunol Methods. 371:97–105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suso EM, Dueland S, Rasmussen AM, Vetrhus
T, Aamdal S, Kvalheim G and Gaudernack G: hTERT mRNA dendritic cell
vaccination: complete response in a pancreatic cancer patient
associated with response against several hTERT epitopes. Cancer
Immunol Immunother. 60:809–818. 2011. View Article : Google Scholar
|
|
33
|
Wang J, Yu L, Li J, Deng R and Wang X:
Characterization of a human telomerase reverse transcriptase
sequence containing two antigenic epitopes with high affinity for
human leucocyte antigen. Biotechnol Appl Biochem. 48:93–99. 2007.
View Article : Google Scholar
|
|
34
|
Vonderheide RH, Anderson KS, Hahn WC,
Butler MO, Schultze JL and Nadler LM: Characterization of
HLA-A3-restricted cytotoxic T lymphocytes reactive against the
widely expressed tumor antigen telomerase. Clin Cancer Res.
7:3343–3348. 2001.PubMed/NCBI
|
|
35
|
Schroers R, Huang XF, Hammer J, Zhang J
and Chen SY: Identification of HLA DR7-restricted epitopes from
human telomerase reverse transcriptase recognized by
CD4+ T-helper cells. Cancer Res. 62:2600–2605.
2002.PubMed/NCBI
|
|
36
|
Schroers R, Shen L, Rollins L, Rooney CM,
Slawin K, Sonderstrup G, Huang XF and Chen SY: Human telomerase
reverse transcriptase-specific T-helper responses induced by
promiscuous major histocompatibility complex class II-restricted
epitopes. Clin Cancer Res. 9:4743–4755. 2003.
|
|
37
|
Tang XD, Wang GZ, Guo J, Lu MH, Li C, Li
N, Chao YL, Li CZ, Wu YY, Hu CJ, Fang DC and Yang SM: Multiple
antigenic peptides based on H-2Kb-restricted CTL epitopes from
murine heparanase induce a potent antitumor immune response in
vivo. Mol Cancer Ther. 11:1183–1192. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Parker KC, Bednarek MA and Coligan JE:
Scheme for ranking potential HLA-A2 binding peptides based on
independent binding of individual peptide side-chains. J Immunol.
152:163–175. 1994.PubMed/NCBI
|
|
39
|
Niu BL, Du HM, Shen HP, Lian ZR, Li JZ,
Lai X, Wei SD, Zou LQ and Gong JP: Myeloid dendritic cells loaded
with dendritic tandem multiple antigenic telomerase reverse
transcriptase (hTERT) epitope peptides: a potentially promising
tumor vaccine. Vaccine. 30:3395–3404. 2012. View Article : Google Scholar
|
|
40
|
Murofushi Y, Nagano S, Kamizono J,
Takahashi T, Fujiwara H, Komiya S, Matsuishi T and Kosai K: Cell
cycle-specific changes in hTERT promoter activity in normal and
cancerous cells in adenoviral gene therapy: a promising implication
of telomerase-dependent targeted cancer gene therapy. Int J Oncol.
29:681–688. 2006.
|
|
41
|
Jacob D, Davis J, Zhu H, Zhang L, Teraishi
F, Wu S, Marini FC III and Fang B: Suppressing orthotopic
pancreatic tumor growth with a fiber-modified adenovector
expressing the TRAIL gene from the human telomerase reverse
transcriptase promoter. Clin Cancer Res. 10:3535–3541. 2004.
View Article : Google Scholar
|
|
42
|
Kyo S and Inoue M: Complex regulatory
mechanisms of telomerase activity in normal and cancer cells: how
can we apply them for cancer therapy? Oncogene. 21:688–697. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iliopoulos D, Satra M, Drakaki A,
Poultsides GA and Tsezou A: Epigenetic regulation of hTERT promoter
in hepatocellular carcinomas. Int J Oncol. 34:391–399.
2009.PubMed/NCBI
|
|
44
|
Gu J, Zhang L, Huang X, Lin T, Yin M, Xu
K, Ji L, Roth JA and Fang B: A novel single tetracycline-regulative
adenoviral vector for tumor-specific Bax gene expression and cell
killing in vitro and in vivo. Oncogene. 21:4757–4764. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao P, Wang C, Fu Z, You Y, Cheng Y, Lu
X, Lu A, Liu N, Pu P, Kang C, Salford LG and Fan X: Lentiviral
vector mediated siRNA knock-down of hTERT results in diminished
capacity in invasiveness and in vivo growth of human glioma cells
in a telomere length-independent manner. Int J Oncol. 31:361–368.
2007.
|
|
46
|
Liu X, Huang H, Wang J, Wang C, Wang M,
Zhang B and Pan C: Dendrimers-delivered short hairpin RNA targeting
hTERT inhibits oral cancer cell growth in vitro and in vivo.
Biochem Pharmacol. 82:17–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gandellini P, Folini M, Bandiera R, De
Cesare M, Binda M, Veronese S, Daidone MG, Zunino F and Zaffaroni
N: Down-regulation of human telomerase reverse transcriptase
through specific activation of RNAi pathway quickly results in
cancer cell growth impairment. Biochem Pharmacol. 73:1703–1714.
2007. View Article : Google Scholar
|
|
48
|
Kota SK and Balasubramanian S: Cancer
therapy via modulation of micro RNA levels: a promising future.
Drug Discov Today. 15:733–740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hao ZM, Luo JY, Cheng J, Li L, He D, Wang
QY and Yang GX: Intensive inhibition of hTERT expression by a
ribozyme induces rapid apoptosis of cancer cells through a telomere
length-independent pathway. Cancer Biol Ther. 4:1098–1103. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sachsinger J, Gonzalez-Suarez E, Samper E,
Heicappell R, Muller M and Blasco MA: Telomerase inhibition in
RenCa, a murine tumor cell line with short telomeres, by
overexpression of a dominant negative mTERT mutant, reveals
fundamental differences in telomerase regulation between human and
murine cells. Cancer Res. 61:5580–5586. 2001.
|
|
51
|
Cesare AJ and Reddel RR: Alternative
lengthening of telomeres: models, mechanisms and implications. Nat
Rev Genet. 11:319–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
